PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2022581
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2022581
Injectable Cement Market size was valued at US$ 1,152.72 Million in 2025, expanding at a CAGR of 5.76% from 2026 to 2033.
Injectable cement is offered in pre-mix, liquid, and powder forms for medical use. It is applied to fill gaps between bone and implants, providing adhesion and flexibility, particularly in procedures like hip surgery. The cement enhances bone stability and supports proper posture during surgical interventions. Its primary function is to transfer body weight from the implant to the bone while securing the implant, improving overall load-bearing capacity.
The Injectable Cement Market represents a niche segment within construction and healthcare, focusing on materials used in applications such as orthopedic procedures. For instance, in 2024, according to the British Orthopaedic Association, over 6.5 million musculoskeletal cases were reported in the UK, with projections expected to exceed 7 million by 2030, while demand for major procedures such as hip and knee replacements is rising at annual rates of over 5% and 3% respectively. The association notes capacity constraints, needing up to 160% of pre-pandemic levels to clear backlogs. Thus, rising surgical demand and capacity constraints drive the injectable cement market.
Injectable Cement Market- Market Dynamics
Growing Elderly Population To Drive Market Growth
The growing elderly population is driving increased demand for healthcare and supportive services, as aging individuals require more medical care, assisted living, and specialized facilities to maintain health and quality of life. Many older adults in low- and middle-income countries face heightened care challenges, prompting WHO's Decade of Healthy Ageing to promote integrated care and supportive environments. For instance, in 2024, according to the World Health Organization, the population aged 60 years and above in the European region is projected to reach nearly 30% of the total population by 2050, increasing from around 25% in recent years, reflecting a significant demographic shift. The organization further highlights that ageing is accelerating globally, with rising life expectancy and older adults needing long-term care. The global ageing trend is driving greater demand for healthcare, long-term care, and supportive services worldwide.
The Global Injectable Cement Market is segmented on the basis of Type of Injectable Cement, Material Composition, Distribution Channel, Application, End User, and Region.
Orthopedic surgery, spinal procedures, and dental surgery account for a significant share of the injectable cement market due to their consistent demand and suitability for minimally invasive treatments. For instance, in June 2024, according to the American Society of Plastic Surgeons Org., nearly 25.4 million minimally invasive cosmetic procedures were performed, reflecting a 7% increase compared with 2022, with neuromodulator injections alone accounting for over 9.4 million procedures. Thus, increasing adoption of minimally invasive procedures is driving demand for injectable cement across surgical applications.
In the Injectable Cement Market, the PMMA (Polymethyl methacrylate) Cement segment holds a significant share in the material composition segment, due to its widespread use in orthopedic, spinal, and dental procedures, driven by its high mechanical strength and quick setting properties for effective bone stabilization. In 2025, Stryker continued to expand its PMMA-based bone cement portfolio with a focus on antibiotic-loaded formulations designed to improve infection control and enhance outcomes in orthopedic and spinal procedures, supporting minimally invasive surgical techniques. Hence, continuous advancements in PMMA formulations and rising surgical demand are supporting segment growth.
Injectable Cement Market- Geographical Insights
Among all the regions, Asia-Pacific accounts for a significant share of the injectable cement market.
The Asia-Pacific injectable cement market is expanding due to rising healthcare awareness, growing hospital infrastructure, and increasing government healthcare spending. For instance, in 2025, according to the India Brand Equity Foundation, India's healthcare sector is witnessing rapid expansion with the number of hospitals increasing to over 82,000, more than 1.5 million hospital beds, and annual healthcare revenue expected to grow to USD 372 billion by 2025. IBEF notes rising investments in medical devices, telemedicine, diagnostics, and government-backed healthcare networks. Hence, rising healthcare infrastructure, investments, and government support are driving growth in the Asia-Pacific injectable cement market.
Australia Injectable Cement Market- Country Insights
Australia is seeing significant growth in the injectable cement market, driven by increasing healthcare infrastructure development and rising demand for orthopedic procedures. Growing hospital networks and government initiatives are boosting injectable cement use. For instance, according to the Building Health Commissioning Capability of Australia's Primary Health Networks study, Australia established 31 Primary Health Networks (PHNs) in 2015 to streamline primary care and support coordination with local hospitals and other providers. Expanding healthcare infrastructure and coordinated primary care networks are driving injectable cement adoption in Australia.
Companies such as Stryker, Johnson & Johnson, Heraeus Medical, Smith & Nephew, and B. Braun Melsungen AG are driving growth in the injectable cement market through diverse products and application leadership. Their financial performance, R&D investments, market strategies, regional presence, and product launches are analyzed to assess their market influence. In October 2025, Heraeus Medical expanded its orthopedic biomaterials portfolio with the launch of its heracure products pre-filled calcium phosphate-based bone substitute biomaterials designed for easy syringe application in bone defects and regenerative procedures, introduced at DKOU 2025. Strategic product launches and innovation are strengthening these companies' influence in the injectable cement market.
In March 2026, Stryker Corporation highlighted continued orthopaedic innovations at the AAOS 2026 Annual Meeting, including enhancements to its Triathlon(R) Total Knee System and expanded Mako SmartRobotics(TM) offerings, demonstrating its ongoing technology rollout in orthopaedic care.
In March 2026, Stryker introduced DirectInject, its first on-demand, self-setting hydroxyapatite (HA) cement designed for cranial defect repair and bony contour augmentation without manual mixing, enhancing ease of use and procedural efficiency in neurosurgical and orthopaedic applications.